Approval from NSW Health is required to prescribe, supply or administer psilocybine or MDMA.
There are currently no psilocybine or MDMA products registered on the Australian Register of Therapeutic Goods (ARTG). Access is available only through the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme and NSW Health approval requirements.
Note: A NSW Health approval is different from a PBS Authority approval. A PBS Authority provides access to a medicine at a subsidised cost, while a NSW Health approval authorises prescribing, supplying or administering the medicine in circumstances specified under NSW legislation.
Since July 2023, Schedule 8 of Poisons Standard has included:
Only Ahpra-registered psychiatrists authorised under the TGA Authorised Prescriber Scheme and approved by NSW Health may prescribe, supply or administer these substances in NSW.
Access is limited to:
The use of psilocybine or MDMA for any other purpose remains limited to approved medical or scientific research, including clinical trials. For more information, see Clinical trial schemes.
[back to top]
Before applying to NSW Health, a psychiatrist must obtain authorisation under the TGA Authorised Prescriber Scheme. To become an authorised prescriber, the psychiatrist must:
Further information is available from the TGA's Access pathways for MDMA and psilocybine.
Once authorised by the TGA, psychiatrists must submit an Application for approval - Psilocybine or MDMA to NSW Health.
Before applying, refer to the guidance provided in Approval applications - supplementary information.
Applications are generally processed within 30 business days.
Applications are generally approved where the applicant:
Once all approvals and authorisations have been obtained, the authorised psychiatrist, or a person acting on their behalf, may also need to obtain an import licence and permit from the Office of Drug Control to import products containing psilocybine or MDMA. For further information please see TGA.
NSW Health requires the submission of treatment and adverse event data at 3, 6 and 12 months following completion of a treatment course. These are to be submitted Data collection form.